

11/2/87
Jen - Linda -

THE

CANCER LETTER

P.O. Box 2370 Reston, Virginia 22090 Telephone 703-620-4646

Vol. 13 No. 42

Oct. 30, 1987

© Copyright 1987 The Cancer Letter Inc.
Subscription: \$160 year North America,
\$175 year elsewhere

Fischinger Named HHS AIDS Coordinator; DeVita Appoints Maryann Roper Acting Deputy Director

NCI Deputy Director Peter Fischinger has been appointed the Public Health Service AIDS coordinator by HHS Secretary Otis Bowen, effective last week. Fischinger will be responsible for coordination of all HHS AIDS research, (Continued to page 2)

In Brief

Fisher, Moore, Metcalf To Share Hammer Prize; NCAB Hearing On Organ Systems Program Dec. 3

ARMAND HAMMER annual prize for outstanding research in cancer will be divided among Bernard Fisher, Univ. of Pittsburgh and chairman of the National Surgical Adjuvant Breast & Bowel Project; Malcolm Moore, Memorial Sloan-Kettering Cancer Center; and Donald Metcalf, Melbourne. Fisher was recognized for his landmark studies which have had such an impact on treatment and understanding of breast cancer. Moore and Metcalf played major roles in development of colony stimulating factors as promising new immunotherapy of cancer. Hammer, chairman of the President's Cancer Panel, announced the winners at last week's meeting of the Panel in Pittsburgh. . . . DEWITT GOODMAN, professor of preventive medicine at Columbia Univ. College of Physicians & Surgeons, will receive the \$25,000 annual Bristol-Myers award for nutrition research. Goodman is a leading scientist in the field of vitamin A and retinoids. . . . NANCY BRINKER, member of the National Cancer Advisory Board, has been named as one of 10 to receive the Northwood Institute's Distinguished Women's Award for 1987. Brinker is founder and chairman of the Susan G. Komen Foundation. . . . NCAB HEARING on the future of the Organ Systems Program (The Cancer Letter, Oct. 16) will be held Dec. 3 at the Linden Hill Hotel in Bethesda, 8:30 a.m.-5 p.m. The issues: whether to recompute the Organ Systems Coordinating Center grant or turn that role over to NCI staff; whether to keep the organ systems grant portfolio with OSP staff or disperse it among the program divisions. . . . JOSEPH ALLEGRA, chief of medical oncology at the Univ. of Louisville Brown Cancer Center, has never been considered a threat to Jack Nicklaus. But he shot a hole in one recently on the fourth hole of PGA West, in Palm Springs, one of the world's toughest golf courses. Playing partners John Glick and Franco Muggia observed the feat and reported that Allegra returned to over par form the rest of the way.

DCE Board Approves
Recompetition of Two
Major Contracts
. . . Page 4

FDA Approves Ribavirin
Phase 1-2 Trials
. . . Page 2

ONS Congress Plans,
Certification Exams
Set For Pittsburgh
. . . Page 3

ACS Announces New
Awards For Nurses
. . . Page 4

Bristol-Myers Offers
New Fellowships
. . . Page 4

NCI Advisory Group
Other Cancer Meetings
. . . Page 6

RFPs Available
. . . Page 8

Fischinger HHS AIDS Coordinator, Adamson Acting AD For Frederick

(Continued from page 1)

service and education activities and will represent the department on interagency matters relating to AIDS and at White House Domestic Policy Council discussions of AIDS matters.

Fischinger reports to Assistant Secretary for Health Robert Windom. His domain includes all PHS agencies involved in AIDS activities, including NIH, the Centers for Disease Control, Food & Drug Administration, Health Research & Services Administration, and Alcohol, Drug Abuse & Mental Health Administration.

If Congress goes along with the White House request for all HHS AIDS funds to be administered out of the secretary's office, Fischinger will be the one the various agencies will talk with about their allocations. The House appropriations bill does that; the Senate's does not.

Fischinger has not officially left NCI; he has been "detailed" to HHS on a one year assignment, and he remains the NCI deputy director. However, NCI executives do not expect him to return.

The HHS secretary and assistant secretary jobs are political appointments, and those who come in after next year's election may want their own AIDS coordinator, or could decide to do away with that position.

In any case, Fischinger has more than 20 years with the Public Health Service, all of it with NCI, and could take his retirement at any time. If a challenging position as a center director, for instance, were to be offered to him at about this time next year, he probably would be interested. At least two cancer centers are looking for directors--Lombardi at Georgetown, and Hopkins--and there may be others in the near future.

Fischinger, 50, has an MD from Illinois Medical School and a PhD in microbiology from the Univ. of Illinois. He was hired in 1966 by Frank Rauscher, who was then director of the Div. of Cancer Etiology, to work in the viral oncology program.

Fischinger was an NCI associate director for the Frederick Cancer Research Facility when Director Vincent DeVita named him his deputy after Jane Henney left for the Univ. of Kansas. He retained the FCRF responsibility and also assumed the role of NCI AIDS coordinator, heavily involved in vaccine

development, and represented NCI on AIDS related matters at NIH and HHS.

DeVita does not intend to load that much work onto one successor. He has appointed Maryann Roper as acting deputy director and Richard Adamson, director of the Div. of Cancer Etiology, as acting AD for FCRF.

The NCI deputy directorship will have to remain acting as long as Fischinger is on detail to HHS. The Frederick appointment can be made on a permanent basis whenever DeVita can find someone to take it. Adamson says it won't be him; "We're going to recruit someone as soon as possible," he told **The Cancer Letter**.

Roper has been working as special assistant to DeVita, with heavy involvement in AIDS issues. A pediatric oncologist, she had been in the Cancer Therapy Evaluation Program of the Div. of Cancer Treatment. She still works with Philip Pizzo, chief of the Pediatric Branch in the Clinical Oncology Program, on protocols involving interleukin-2 treatment of children with cancer and on treatment of children with AIDS.

Fischinger replaces Gary Noble as AIDS coordinator. He sees the job primarily as one of planning and working with agencies in structuring their AIDS budgets, "to go where the opportunities are," he told **The Cancer Letter**.

FDA Approves Ribavirin Phase 1-2 IND For AIDS Related Conditions

The Food & Drug Administration has approved an investigational new drug protocol for phase 1 and 2 clinical studies of ribavirin for treating patients at high risk with lymphadenopathy syndrome and AIDS related complex.

FDA informed the drug sponsor, ICN Pharmaceuticals Inc. of Costa Mesa, CA, that it had lifted its clinical hold on new studies with ribavirin. Data from two previous trials conducted by the company led to some question of the drug's safety by FDA staff.

"Our review of the complete clinical data provided to the agency on those two trials indicated that our safety concerns are not of sufficient magnitude to withhold approval of further clinical studies designed to assess the safety and efficacy of ribavirin," FDA Commissioner Frank Young said in a letter to ICN.

Young added that "while approval of this protocol means that clinical testing of the

drug for AIDS conditions can resume as specified, it does not constitute a treatment IND approval of ribavirin or an approval for use outside the FDA approved clinical trials."

A treatment IND would permit distribution of the drug to physicians for patients with life threatening disease who have failed standard therapy or for which no standard therapy exists.

ONS To Hold 13th Annual Congress, Certification Exam In Pittsburgh

The world's largest oncologic professional society, which probably is also the most active such organization, is well along in plans for its 13th annual meeting.

The Oncology Nursing Society will hold its congress, as it calls its annual meeting, May 4-7 in Pittsburgh. More than 4,000 of the Society's 11,000 members are expected to attend. Deborah Mayer is ONS president and Deborah Welch-McCaffrey is chairperson of the congress.

Joan Kyes, assistant professor of psychiatry at the Univ. of Pittsburgh, will present the 1988 keynote address on "Professional Survival."

Other congress highlights will include instructional and abstract sessions, round-table events and poster presentations. Member, educational and commercial exhibits will be open daily.

Twenty pregress workshops will be offered May 3 and 4 on a variety of subjects including radiation oncology, pain management, concepts of chemotherapy, bone marrow transplant nursing, issues in office oncology nursing and hospice organization development and administration.

There's more.

Three years ago, ONS established the Oncology Nursing Certification Corp. to develop and conduct certification examinations. A total of 2,072 passed exams held in 1986 and last spring (out of 2,466 who took them). Another 1,050 took the exam this month at six locations around the country; results are not yet in.

The examination will be offered again May 4 in conjunction with the congress in Pittsburgh, and again Oct. 15, 1988, in Phoenix, New Orleans, Minneapolis, New York and Seattle. Registered nurses with at least three years experience and 1,000 hours of oncology nursing within the previous three

years are eligible. They don't have to be ONS members but can save \$50 off the \$200 fee if they are.

In 1982, ONS established another subsidiary, the Oncology Nursing Foundation, to support education of professional nurses in care of cancer patients; public education regarding cancer and cancer care; and research to advance cancer care nursing.

The Foundation recently announced that it will award 10 \$1,000 undergraduate scholarships and two \$2,500 graduate scholarshipsto RNs pursuing BS and MN degrees during the 1988-89 academic year. These scholarships are funded by grants from the Foundation, Burroughs Wellcome Co., Lederle Laboratories, and Adria Labs.

The deadline for completed applications is Jan. 15. Awardees will be announced at the congress.

ONF also announced an RFP for public cancer education. The \$2,500 award is funded by another grant from Lederle. The first public cancer education award went to Nancy Miller this year for a project on breast cancer early detection education for black women.

Nursing Research Course

A grant from NCI will support a one day cancer nursing research course May 4, immediately preceding the congress. The course is designed to strengthen cancer nursing research by providing a national forum for exchange between a small group of distinguished faculty and 10 competitively selected students from different institutions. Applications are invited from doctoral students, recent doctoral graduates and master's prepared nurses. Primary criteria for selection of the trainees are the quality of the research abstract and potential contribution to the field. Abstracts may be submitted for cancer related proposed studies or studies in progress.

Ada Lindsey is program director for the cancer nursing research course, assisted by Marcia Grant, Marilyn Stromborg and Ruth McCorkle. The 1988 faculty members include Barbara Given, Madeline Schmitt, Darlene Mood and Lesley Degner.

Successful applicants will receive travel expenses, four day per diem and paid registration fee for the congress.

For additional information and application forms for the above programs, contact ONS, 1016 Greentree Rd., Pittsburgh, PA 15220, or phone 412/921-7373.

ACS Offers Awards To Nurses For Excellence In Cancer Care

The American Cancer Society has announced a new program of awards for nurses for 1988. The awards will be given to individual nurses who are providing outstanding care to persons with cancer.

Named for former ACS Executive Vice President Lane Adams, the awards emphasize the commitment to excellence in cancer care and will honor a minimum of 10 nurses nationwide.

Registered or licensed nurses may be nominated for these awards if they have a minimum of three years of clinical experience and are currently providing direct care to persons with cancer and their families.

Each recipient will be awarded a stipend of \$1,500 and an additional \$1,000 will be donated in the nurse's name to the institution the nurse represents.

Awards will be presented to nurses practicing in four different settings; cancer care institutions; community, municipal and teaching hospitals; long term care facilities; and community agencies.

Additional information may be obtained from William Lloyd, National Representative coordinator Community Expansion Initiative, ACS, 2340 Des Plaines Ave., Suite 104, Des Plaines, IL 60018, phone 312/298-7030.

Deadline for applications is Dec. 1.

Bristol-Myers Offers Fellowships For Three Years Postgraduate Study

Bristol-Myers is now accepting nominations for five fellowships for postgraduate study in cancer research.

Known as the Bristol-Myers Cancer Research Fellowships, the awards will be made to investigators who have expressed interest in clinical medicine and who also want to undertake advanced study in basic research. Five fellowships, each for a period of three years, will be announced in early 1988 for application to programs beginning in July 1988.

Fellowships will each be in the amount of \$40,000 annually. Candidates must have at least two years of postdoctoral training at the time of the award. All fellowship study must be in the U.S. or Canada.

Deadline for nominations is Nov. 16. Contact Nancy Taussig, Bristol-Myers Cancer Research Fellowships Program, 345 Park Ave., New York 10154, phone 212/546-4337.

DCE Board Approves Recompetition Of Viral Protein, Support Contracts

Recompetition of a contract now being performed jointly for NCI and the National Institute of Allergy & Infectious Diseases, for procurement of purified recombinant viral proteins, was given concept approval last week by the Div. of Cancer Etiology Board of Scientific Counselors.

The material will be used by the Laboratory of Tumor Cell Biology, headed by Robert Gallo, which was moved into DCE earlier this year from the Div. of Cancer Treatment. The material will be made available to the extramural community, DCE Director Richard Adamson said.

The current contract for the two institutes is held by Repligen Inc., at a cost of \$926,000 a year. Total cost of the new NCI-only contract was estimated at \$400,000 a year for three years.

Prem Sarin, who with Flossie Wong-Staal is project officer for the contract, said that Repligen had estimated the purified recombinant viral proteins, in the quantity specified, would cost about \$1.2 million a year. "That's why we're recompeting it," Adamson said.

"There is a definite shortage of this material now," Board Chairman Hilary Koprowski said. "We have to beg for it from Flossie's lab, and they are short, too."

The Board also gave concept approval to recompetition of DCE's contract for technical and logistical support services; to noncompetitive expansion of the contract with the Univ. of Iowa for study of the impact of contaminated drinking water on cancer incidence; and to the noncompetitive renewal of the contract with the Univ. of Ghana Medical School for study of oncogenic and immunosuppressive viruses in West Africa.

The concept statements follow:

Procurement of purified recombinant viral proteins.
Recompetition, three years at \$400,000 a year.

The Laboratory of Tumor Cell Biology is involved in several areas of research which include (a) understanding the role of retroviruses in neoplastic diseases and AIDS; (b) identification and functional characterization of viral and cellular genes implicated in the pathobiology of human retroviruses; (c) investigation of regulatory genes and mechanisms involved in cell growth, differentiation and neoplastic transformation; (d) development of molecular probes for use in studies of normal and aberrant expression of viral and cellular genes; and (e) development of diagnostic and therapeutic reagents.

Basically, the major goal is to develop new approaches to the diagnosis, prognosis of human

diseases particularly neoplastic diseases and AIDS based on studies with clinical material. More recently, the laboratory has been involved in studies on human T-lymphotropic viruses, human B lymphotropic viruses (HBLV), and human immunodeficiency viruses (HIV). These studies have identified HTLV-1 as the etiologic agent for adult T-cell leukemia (ATL) which has been shown to be endemic in Japan, the Caribbean and Africa, and HTLV-3 (now called HIV) as the cause of AIDS. HTLV-2 has been isolated from patients with hairy cell leukemia but has not been linked to any disease.

These human retroviruses preferentially infect T-helper cells, form multinucleated giant cells, and can be transmitted by intimate contact, blood transfusions, intravenous drug abuse and congenital infection. Both HTLV-1 and HTLV-2 can transform the cells they infect, cross react immunologically, share significant sequence homology and are chiefly associated with leukemias and lymphomas. The human immunodeficiency viruses (HIV) on the other hand are cytopathic to the T-cells they infect and recognize T₄ as the receptor for the virus. They can also infect monocyte/macrophages. AIDS is associated with a depletion of T₄ cells, progressive immune deficiency with opportunistic infections, development of Kaposi sarcoma and involvement of the central nervous system.

Although genomes of the leukemia viruses are rather stable, there is considerable variation in the genome of HIV-1 from one isolate to another, especially in the envelope gene. More recently, HBLV has been isolated from patients with chronic fatigue syndrome, but it is not known if it is involved in the etiology of the disease.

With an estimated number of AIDS cases of 270,000 and with the knowledge that there will be over three million HIV-1 infected individuals in the United States by 1991, there has been an extensive focus on the development of vaccine to prevent the disease, and of drugs for the treatment of patients with AIDS. In addition, with the recent isolation of HBLV from patients with chronic fatigue syndrome, there is an urgent need to develop diagnostic reagents for the detection of HBLV antigens and antibodies in the patient's sera.

In our efforts towards the development of sensitive diagnostic tests for RNA and DNA viruses, drugs for treatment and vaccine for AIDS, we would like to obtain milligram quantities of purified recombinant proteins from cloned genes of HIV-1, HIV-2, HTLV-1, HTLV-2, HBLV, and simian immunodeficiency virus (SIV). These proteins will be utilized to carry out structural studies using X-ray crystallography and nuclear magnetic resonance; to study immune response in various animal species and to test the development of neutralizing antibodies against HIV and SIV; and to prepare monoclonal and polyclonal antibodies against various antigens.

Both E-coli and insect cells have been used for the production of large amounts of cloned proteins. Viral proteins produced in bacteria and insect cells have been shown to be immunogenic in several animal species. Antibodies produced against HIV-1 envelope proteins have been found to neutralize HIV-1 in virus neutralization assays. Due to the genetic variability of HIV-1 it may be important to obtain several epitopes responsible for virus neutralization so as to be able to obtain a vaccine preparation which can mount an immune response in the host and be protective against infection with different variants of the virus.

Major objectives of this contract are:

1. To obtain 200-500 mg each of the purified proteins from HIV-1, trs, sor, 3'-orf, reverse transcriptase and protease genes for structural studies, using X-ray diffraction and nuclear magnetic resonance

so as to be able to define the active sites important in the mechanism of action of these gene products.

2. To obtain 5-10 mg each of the purified SIV envelope proteins (gp160 and gp41/32) for animal vaccine studies to determine the immune response in different animal species and to test whether neutralizing antibodies will be generated and to examine if there is any cross neutralization of HIV-1.

3. To obtain 5-10 mg of purified HBLV proteins from cloned DNA fragments for serological studies and to raise polyclonal and monoclonal antibodies for development of sensitive diagnostic tests.

Methods to obtain and purify recombinant viral proteins using E-coli and baculovirus have already been developed and will be utilized for the large scale preparation of these proteins and purification by high performance liquid chromatography.

Technical and logistical support services for the Div. of Cancer Etiology. Recompensation of a contract held by Birch & Davis Associates, Inc. Five years, estimated cost of \$335,000 a year.

Purpose of this contract is to provide services that are not normally available in DCE and to assist the division in logistics and management of activities within the program areas. These support services fall into two major areas--document preparation and conference and meeting management.

The first task area, document preparation, can be divided into two major categories: preparation of documents describing past, current and planned division programs or specific activities; and preparation of handouts, slides, and other graphics for use in presentations to various organizations and groups. The site visit books and the Board of Scientific Counselors books are typical of major documents which would be prepared using the support services provided. In the 1987 fiscal year, the contractor prepared three sets of BSC books and a three volume set of site visit books for the Biostatistics Branch. Under the second task area, conferences and meeting management, the contractor will provide logistical support services for division conferences, meetings and workshops. In general, this will include providing assistance in site selection; preparation and distribution of invitations, agenda, and other pre and post conference materials; hotel and air reservations; reimbursement of participant expenses; recording services, etc.

In the past 12 months, the incumbent contractor helped organize numerous conference/workshops such as the international conference on reproduction and human cancer, sponsored by John Mulvihill in the Clinical Epidemiology Branch; and a workshop on prospects for human papillomavirus vaccines and immunotherapies sponsored by Dr. Schreier in the Biological Extramural Programs Branch.

Through such conferences and workshops, the contractor makes it possible for internal DCE staff (with administrative and managerial responsibilities) to receive input and ascertain the current state of the art regarding a variety of research activities from leading extramural scientists. This contract will function as a task order contract.

Studies on the epidemiology of potentially oncogenic and immunosuppressive viruses in West Africa. Three years, \$45,000 a year, noncompetitive. Univ. of Ghana Medical School is the contractor.

This project is the longest program for the continuing investigation of Burkitt's lymphoma in Africa and has contributed more than 40 articles on the etiology and outcome of therapy of the disease. During the current contract period, work was expanded to include studies of retroviruses in West Africa. Specimens collected are available to investigators.

Expansion of the ongoing case control study of multiple cancer sites and drinking water quality in Iowa. Additional two years, proposed by staff at \$200,000 a year, which will be reduced as the result of the Board's modification of the proposal. The Univ. of Iowa is the incumbent contractor. Noncompetitive.

DCE staff had proposed that two cancer sites, stomach and lung, be added to the six currently in the study contract, along with doubling the number of newly diagnosed bladder cancer cases, from 600 to 1,200. The size of the population based control series, currently 1,500, would be expanded by 900. No further enrollment of additional cases of the other sites--colon, rectum, brain, kidney and pancreas--is planned.

Board members objected to the addition of stomach and lung cancer cases, arguing that it was unlikely a significant number could be related to drinking water. Noel Weiss offered a motion to approve the additional bladder cancer cases, which was passed unanimously.

Board member Peter Magee, commenting that "it would be a shame if the nitrate portion (suggested as one of the contaminants that might impact on stomach cancer) is not included," suggested that staff develop another concept proposal for that part of the study. "This doesn't close the door on other studies," Koprowski said. "They can come back with others."

NCI Advisory Group, Other Cancer Meetings For Nov., Dec., Future

Clinical Oncology and Cancer Nursing--Nov. 1-4, Madrid. 4th European conference. Contact SIASA Congresos, Paseo de la Habana, 134, Madrid 28036, Spain. Also, satellite meeting, European Society for Psychosocial Oncology. Contact ESPO Secretary J. De Haes, Institute of Social Medicine, Univ. of Leiden, Wassenaarweg 62, 2333 AL Leiden, Netherlands.

Perspectives in Cancer Treatment--Nov. 1, Palacio de Congresos, Madrid. Contact Science and Medicine, 909 Third Ave., New York 10022, phone 212/909-9643.

International Society for Interferon Research--Nov. 2-6, Washington DC. Contact ASM Meetings Office, 1913 Eye St. NW, Washington DC 20006, phone 202/833-9680.

Div. of Cancer Biology & Diagnosis Board of Scientific Counselors--Nov. 3, NIH Bldg 31 Rm 10, 9 a.m., open.

Progress in In Vitro Toxicology--Nov. 4-5, Baltimore. Contact Jeanne Ryan, Program Coordinator, Office of Continuing Education, Johns Hopkins Medical Institutions, 720 Rutland Ave., Baltimore 21205, phone 301/955-6046.

Bone Marrow Transplantation: Clinical Intervention--Nov. 4-6, New York. Contact Lisa Griffin, Course Secretary, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York 10021, phone 212/794-7019.

French Radiology Congress--Nov. 4, Villejuif, France. Contact Mrs. N. Leroy, Radiology Dept., Inst. Gustave-Roussy, 30 rue C. Demoulin, 94805 Villejuif, Cedex, France.

Venezuelan Congress of Oncology and Congress of Oncology Nursing--Nov. 4-7, Maracaibo, Venezuela. Contact Sociedad Venezolana de Oncologia, Torre El Colegio Urb. Santa Fe, Piso 15, Oficina C-2, Caracas 1080, Venezuela.

Cancer Research Manpower Review Committee--Nov. 5-6, Bethesda Ramada Inn, open Nov. 5 8:30-9 a.m.

Ethical and Legal Issues in Cancer Nursing--Nov. 5, Brisbane. 11th annual Oncology Nursing Seminar. Contact Sr. Susan Goddard, Secretary, Oncology Nurses Group, Queenisland Cancer Fund, PO Box 201, Spring Hill, Qld., Australia 4000.

Integrated Management of Head & Neck Cancer--Nov 5-9, Grantham, Lincs, UK. Contact Dr. P.J. Bradley, Univ. Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK.

Cancer Prevention & Detection: Update 1987--Nov. 5, Youngstown, OH. Contact Dr. Sudershan Garg, St. Elizabeth Hospital Medical Center, 1044 Belmont Ave., Youngston 44501, phone 216/746-7211 Ext. 3694.

Cancer Management--Nov. 6-7, Hershey Hotel, Philadelphia. Contact Cancer Dept., American College of Surgeons, 55 E. Erie St., Chicago, IL 60611.

Breast Cancer Symposium--Nov. 6-7, Century City, CA. Contact Helen McGrane, PhD, Saint Joseph Medical Center, Buena Vista & Alamada, Burbank 91505, phone 818/843-5111 Ext. 7241.

Genetic Mechanisms and Cancer--Nov. 8-11, Westin Galleria Hotel, Houston. 40th annual symposium on Fundamental Cancer Research. Contact Office of Conference Services, UT M.D. Anderson Hospital, 1515 Holcombe Blvd, Houston 77030, phone 713/792-2222.

Xth Peruvian Cancer Congress--Nov. 8-12, Lima. Contact Dr. O. Barriga, President, Xth Peruvian Cancer Congress, Instituto Nacional de Enfermedades Neoplasicas, Avenida Alfonso Ugarte 825, Lima, Peru.

XIIIth International Symposium for Comparative Research on Leukemia and Related Diseases--Nov. 8-14, Jerusalem. Contact Dr. David Yohn, Secretary-General, Suite 302, 410 W. 12th Ave., Columbus, OH 43210; or Dr. Ze'ev Trainin, Kimron Veterinary Institute, PO Box 12, Beit Dagan 50200, Israel.

Immunity to Cancer--Nov. 9-11, Williamsburg, VA. Second conference. Contact Carole Kirby, Biological Response Modifiers Program, Div. of Cancer Treatment, NCI Frederick Cancer Research Facility, Bldg 567 Rm 138, Frederick, MD 21701.

Smoking or Health--Nov. 9-12, Tokyo. Contact Secretariat, 6th Conference on Smoking or Health, c/o Japan Convention Services Inc., Nippon Press Center Bldg., 2-2-1, Uchisaiwai-cho, Chiyoda-ku, Tokyo 100, Japan.

Oral Cancer and Jaw Tumors--Nov. 9-14, Singapore. Contact 1st International Congress of Oral Cancer and Jaw Tumors, Dept. of Oral Surgery, Faculty of Dentistry, National Univ. of Singapore, Lower Kent Ridge, Singapore 0511.

Cancer Nursing Update--Nov. 10, London. Contact Institute of Oncology, Marie Curie Memorial Foundation, 28 Belgrave Square, London, SW1X 8QG, UK.

Recent Advances in the Systemic Therapy of Genitourinary Malignancies--Nov. 11-14, Westin Galleria Hotel, Houston. Contact Office of Conference Services, UT M.D. Anderson Hospital, 1515 Holcombe Blvd, Houston 77030, phone 713/792-2222.

Cincinnati Cancer Conference VI: Sarcoma--Nov. 13-14, Cincinnati. Contact Tom O'Connor, CME Coordinator, Bethesda Hospital, 619 Oak St., Cincinnati, OH 45206.

1st International Endocurietherapy/Hyperthermia Conference and Workshop--Nov. 13-28, Bombay/Hyderabad/Delhi, India. Contact Professional Education Div., Tata Memorial Hospital, Tata Memorial Centre, Bombay 400 012, India.

Biliary Tract Disease--Dilemmas and Decisions--Nov. 14, Alta Bates Hospital Auditorium, Berkeley. Contact Mary Grim, Medical Education Coordinator, 3001 Colby St., Berkeley, CA 94705, phone 415/540-1420.

National Cancer Advisory Board--Nov. 16-17, NIH Bldg 31 Rm 6, 8:30 a.m. both days, all open. Annual program review. The Committee on Planning & Budget will meet Nov. 16 in open session immediately after the Board meeting, in Bldg 31 Rm 7.

12 Annual Symposium on Chemotherapy--Nov. 16, Paris. Contact L. Saint Ange, Organisation des Reunions Scientifiques, Institut Gustave-Roussy, 39, rue C.-Desmouins, 94805 Villejuif, Cedex, France.

Clinical Oncology Society of Australia--Nov. 16-18, Melbourne. Annual scientific meeting. Contact COSA, GPO Box 4708, Sydney NSW 2001, Australia.

Sixth Annual Ella T. Grasso Memorial Conference--Nov. 18, New Haven, CN. Contact Yale Univ. School of Medicine, Office of Graduate and Continuing Education,

333 Cedar St., Box 3333, New Haven 06510, phone 203/785-4578.

Dedication of the R. Lee Clark Clinic Building--Nov. 19, 3 p.m., M.D. Anderson Hospital & Tumor Institute, Houston.

President's Cancer Panel--Nov. 20, NIH Bldg 31 Rm 11A23, 9:30 a.m., open.

Breast Cancer Chemoprevention--Nov. 20, Essex House, New York. First international workshop and conference. Contact Chemoprevention Workshop, Div. of General Oncology, Mount Sinai Medical Center, One Gustave L. Levy Pl., New York 10029, phone 212/369-5440.

Neoplasia and the Nervous System--Nov. 21, Cleveland. Contact Barbara Guy, R. Livingston Ireland Cancer Center, Univ. Hospitals of Cleveland/Case Western Reserve Univ., 2074 Abington Rd., Cleveland 44106, phone 216/844-7856.

Lung Cancer: The Problems of Prevention--Nov. 20, London. Contact Administrative Officer, Institute of Oncology, Marie Curie Memorial Foundation, 28 28 Belgrave Square, London SW1X 8QG, UK.

Radiotherapy: Cure Without Mutilation--Nov. 20, Rotterdam. Contact B. Lowenberg, Dr. Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, Netherlands.

Neoplasia and the Nervous System--Nov. 21, Ireland Cancer Center, Cleveland. Contact Barbara Guy, PhD, Ireland Cancer Center of Univ. Hospitals of Cleveland and Case Western Reserve Univ. School of Medicine, 2074 Abington Rd., Cleveland, OH 44106, phone 216/844-7856.

Colorectal Cancer and The Care of the Patient with Cancer--Nov. 24-26, London. Contact Institute of Oncology, Marie Curie Memorial Foundation, 28 Belgrave Square, London SW1X 8QG, UK.

4th Panhellenic Oncological Conference--Nov. 26-28, Athens. Contact D. Lainiotou, Medical Library A. Aragin Oncological Hospital of Kifisia, N. Kifisia, Greece.

Pathology of Pediatric Tumors--Nov. 30-Dec. 3, Genova. Contact G. Rossini, c/o Scientific Direction G. Gaslimi, Childrens Hospital, Via 5 May 39, 16148 Genova, Italy.

Clinical Intervention with AIDS--Dec. 2-4, New York. Contact Lisa Griffin, Course Secretary, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York 10021, phone 212/794-7019.

Advanced Cancer in Later Years: A Nursing Challenge--Dec. 3, Ruth Taylor Geriatric & Rehabilitation Institute, Westchester County Medical Center, Hawthorne, NY. Contact Sr. Patricia Sheridan, Coordinator, Continuing Professional Education, Calvary Hospital, 1740 Eastchester Rd., Bronx, NY 10461, phone 212/863-6900.

Cancer Therapy Program Project Review Committee--Dec. 3-4, Chevy Chase Holiday Inn, open Dec. 3 8-8:30 a.m.

Cancer Preclinical Program Project Review Committee--Dec. 3, Bethesda Holiday Inn, open 8:30-8:45 a.m.

Cancer Clinical Investigation Review Committee--Dec. 3-4, Omni Shoreham Hotel, Washington DC, open Dec. 3 8:30-9 a.m.

National Cancer Advisory Board Committee on Organ Systems Programs--Dec. 3, Linden Hill Hotel, Bethesda, 8:30 a.m.-5 p.m., open.

Cancer Center Support Review Committee--Dec. 4, Hyatt Regency Hotel, Bethesda, open 10 a.m.-3:30 p.m.

Clinical Cancer Program Project Review Committee--Dec. 4, Howard Johnson Inn, Crystal City, VA, open 12-12:30 p.m.

Societa Italiana di Chirurgia Oncologica--Dec. 5-8, Genova. Contact Dr. Fausto Badelino, Chief, Div. of Surgical Oncology, Istituto Tumori Genova, V. Benedetto XV, 10, 16132 Genova, Italy.

Antigens of Human Pancreatic Adenocarcinoma: Their

Role in Diagnosis and Therapy--Dec. 7-8, Rockville, MD. Organ Systems Programa workshop. Contact Dr. Harold Asch, Organ Systems Coordinating Center, Roswell Park Memorial Institute, 666 Elm St., Buffalo, NY 14263, phone 716/845-2317.

Frederick Cancer Research Facility Advisory Committee--Dec. 8, NIH Bldg 31 Rm 9, open 8 a.m.-noon.

Interferons and Tumor Necrosis Factors Advances in Clinical Research--Dec. 9, Brussels. Contact D. Eeckhoudt, Executive Secretary, EORTC Data Center, Boulevard de Waterloo 125, 1000 Brussels, Belgium.

Radiation and Cancer Risk--Dec. 9-10, Oslo. Contact Norwegian Cancer Society, Huitfeldtsgt. 49, 0253 Oslo 2, Norway.

Regulation of Proliferation and Differentiation in Normal and Neoplastic Cells--Dec. 10-11, Westin Hotel, Boston. 10th annual Bristol-Myers Symposium on Cancer Research. Contact Nancy Taussig, Bristol-Myers, 345 Park Ave., New York 10154, phone 212/546-4337.

Clinical Aspects of HIV Infection--Dec. 10-11, Brussels. Contact D. Eeckhoudt, EORTC Data Center, Blvd. de Waterloo 125, 1000 Brussels, Belgium.

10th Annual San Antonio Breast Cancer Symposium--Dec. 11-12, San Antonio. Contact Terri Coltman, RN, Cancer Therapy & Research Center, 4450 Medical Dr., San Antonio, TX 78229.

Cancer Management Course--Dec. 11-12, Nashville. Contact William Johnston, MD, FACS, Cancer Dept., American College of Surgeons, 55 E. Erie St., Chicago 60611, phone 312/664-4050.

Second Tokyo Symposium on Prostate Cancer--Dec. 11-12, Tokyo. Contact Dr. Hidetoshi Yamanaka, Dept. of Urology, School of Medicine, Gunma Univ., Maebashi, Gunma-ken 371, Japan.

Annual Symposium on Carcinological General Surgery--Dec. 11-12, Villejuif, France. Contact N. Chassaing, Dept. of General Surgery, Institute Gustave-Roussy, 39, rue C.-Desmoulins, 94805 Villejuif Cedex, France.

FUTURE MEETINGS

29th Annual Postgraduate Institute for Pathologists in Clinical Cytopathology--February through April 1988, Home Study Course A; April 25-May 6, In Residence Course B. Application and preregistration advised at earliest possible date. Complete preregistration must be accomplished before March 25 unless by special arrangement. Contact John Frost, MD, 604 Pathology Bldg., Johns Hopkins Hospital, Baltimore, MD 21205.

22nd Annual Clinical Symposium--Feb. 26-27, 1988. Open to all physicians but limited to the first 200 who register. No registration fees. Current results in treatment of children with cancer and other catastrophic diseases. Contact Joseph Simone, MD, Director, St. Jude Children's Research Hospital, Box 318, Memphis, TN 38101.

Molecular Biology of T Cell Differentiation and Function--March 24-25, Univ. of North Carolina (Chapel Hill). 12th Annual Symposium of the Lineberger Cancer Research Center. Contact the Cancer Center, School of Medicine, UNC, Chapel Hill, NC 27514, phone 919/966-3036.

Biologic Response Modifiers--April 15-16, Lexington, KY. First Markey Cancer Center Symposium. Contact Hilary Wood, RN, 606/257-4500.

National Workshop for Clinical Oncologists--April 22-23, Keystone, CO. Diagnostic imaging techniques, including MRI, CT and ultrasound, for use by clinical oncologists in the management of cancer. Contact UCLA Symposia, Molecular Biology Institute 103, UCLA, Los Angeles 90024, phone 213/206-6292.

Oncology Nursing Society 13th Annual Congress--May 4-7, David Lawrence Convention Center, Pittsburgh. Workshops, scientific sessions, lectures, roundtable and poster sessions, educational exhibits. Contact

Nancy Berkowitz, ONS, 1016 Greentree Rd, Pittsburgh, PA 15220.

American Assn. for Cancer Research--May 25-28, New Orleans. 79th annual meeting, New Orleans Convention Center. Contact AACR, Temple Univ. School of Medicine, West Bldg Rm 301, Philadelphia, PA 19140.

International Symposium on Therapeutic Progress in Urological Cancers--June 29-July 1, Hotel Inter-Continental, Paris.

RFP Available

The request for proposals described here pertains to a contract planned for award by the National Cancer Institute. NCI listings will show the phone number of the Contracting Officer or Contract Specialist who will respond to questions. Address requests for NCI RFPs, citing the RFP number, to the individual named, the Blair building room number shown, National Cancer Institute, NIH, Bethesda MD 20892. Proposals may be hand delivered to the Blair building, 8300 Colesville Rd., Silver Spring MD, but the U.S. Postal Service will not deliver there. RFP announcements from other agencies will include the complete mailing address at the end of each.

RFP NCI-CM-87240-72

Title: P-antifolate screen for drugs against opportunistic infections in patients with AIDS
Deadline: Dec. 18

The National Cancer Institute's Developmental Therapeutics Program is seeking a contractor to screen folate analogs and analogs of p-aminobenzoic acid (PABA) for their potential as therapeutic agents in the treatment of opportunistic infections observed in patients with AIDS.

NCI expects to award one incrementally funded contract for a period of five years. The contract will be "level of effort" specifying that the contractor is to furnish 30,550 labor hours over five years.

Experiments will be conducted to screen folate analogs for differential inhibitory activity against dihydrofolate reductase isolated from pneumocystis carinii and/or toxoplasma gondii and a mammalian source. Analogs of PABA will be screened for inhibition of dihydropterolate synthase isolated from at least one of the pathogenic organisms. Selected agents of interest identified by the initial enzyme screens will be tested for their ability to be taken up by intact cells. Protection of intact cells from selected dihydrofolate reductase inhibitors by leucovorin also may be evaluated. Compounds to be studied will be selected and assigned by the government.

The offeror may propose to work with dihydrofolate reductase and dihydropterolate synthase obtained from both pneumocystis carinii and T. gondii or either. It is preferred that offerors propose to conduct studies with enzymes isolated from both organisms. However, if only one source is proposed, P. carinii would be the one source of choice.

The offeror may not be a pharmaceutical or chemical firm as compounds of a commercially confidential nature (discreet) may be evaluated. Also since structural formulas of discreet materials may be provided by the government on occasion, the organization must be willing to sign a confidentiality of information statement.

The principal investigator should have an MD or PhD in one of the relevant biological sciences (or

equivalent experience), should have managerial experience and experience in protozoology or in enzymology and should devote approximately 20 percent of their time to the project.

Contracting Officer: Jackqueline Ballard
RCB Blair Bldg Rm 228
301/427-8737

RFP NCI-CM-87247-22

Title: Master agreement for chemical synthesis
Deadline: Approximately Dec. 31

The Drug Synthesis & Chemistry Branch of the Div. of Cancer Treatment's Developmental Therapeutics Program is seeking proposals from offerors with the capability of providing services for the synthesis of a variety of organic and inorganic compounds. The primary focus will be on the synthesis of organic compounds. DTP is resoliciting additional master agreement holders for this project. Current master agreement holders need not respond.

Master agreements are competitively negotiated and awarded to more than one organization. It is planned that such agreements will be awarded on or about July 20, 1988, to expire on Sept. 29, 1989. The master agreements will not be funded per se. After award, master agreement holders will be invited to bid competitively on appropriate master agreement orders (MAOs) as they are issued.

Each MAO will be designed to accomplish a specific task as promptly as possible and will be awarded on a completion or level of effort basis, as determined by the contracting officer.

The objective of this project is the resynthesis of known compounds of varying degrees of complexity for confirmatory testing identified by both the new in vitro screen and the in vivo screens. Approximately 200 compounds will be synthesized during each contract year and these will comprise approximately 20 individual MAOs. It is expected that MAOs will be issued quarterly.

Contract Specialist: Elizabeth Moore
RCB Blair Bldg Rm 216
301/427-8737

RFP NCI-CN-85060-43

Title: Research support services for diet, nutrition and cancer prevention
Deadline: Approximately Dec. 20

This is a 100 percent set aside for small business. For the purpose of this procurement, a small business is classified as such if its average annual receipts for its preceding three fiscal years do not exceed \$3.5 million.

The primary purpose of this acquisition is to provide research support services for diet and nutrition and cancer prevention activities. These services and deliverables will provide basic source and analytical materials for evaluation of hypotheses which might result in concepts for new research projects for RFA and RFP initiatives; and preparation of Div. of Cancer Prevention & Control documents on diet, graphs, review articles and position papers for task force review and analysis.

Contract Specialist: Diana Wheeler
RCB Blair Bldg Rm 2A07
301/427-8745

NCI CONTRACT AWARDS

Title: Support contract for public health initiative
Contractor: Maximus Inc., \$1,423,601

The Cancer Letter _ Editor Jerry D. Boyd

Associate Editor Patricia Williams

Published forty-eight times a year by The Cancer Letter, Inc., P.O. Box 2370, Reston, Virginia 22090. Also publisher of The Clinical Cancer Letter. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.